Your browser doesn't support javascript.
loading
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models.
Brinch, Shoshy A; Amundsen-Isaksen, Enya; Espada, Sandra; Hammarström, Clara; Aizenshtadt, Aleksandra; Olsen, Petter A; Holmen, Lone; Høyem, Merete; Scholz, Hanne; Grødeland, Gunnveig; Sowa, Sven T; Galera-Prat, Albert; Lehtiö, Lari; Meerts, Ilonka A T M; Leenders, Ruben G G; Wegert, Anita; Krauss, Stefan; Waaler, Jo.
Afiliação
  • Brinch SA; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Amundsen-Isaksen E; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Espada S; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Hammarström C; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Aizenshtadt A; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Olsen PA; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Holmen L; Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Høyem M; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Scholz H; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Grødeland G; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Sowa ST; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Galera-Prat A; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Lehtiö L; Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Meerts IATM; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Leenders RGG; Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Wegert A; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Krauss S; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Waaler J; Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland.
Cancer Res Commun ; 2(4): 233-245, 2022 04.
Article em En | MEDLINE | ID: mdl-36873622
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias do Colo / Tanquirases Limite: Animals / Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias do Colo / Tanquirases Limite: Animals / Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega